{
    "PMC4549947_4": {
    "html_table": "<table><thead><tr><th></th><th>Females</th><th>Males</th><th>Hispanics</th><th>African American</th><th>Alcohol use</th></tr></thead><tbody><tr><td>DRD2 rs6277 (executive function)</td><td>1.3</td><td>3.5 (1.5–5.5)<br/>p = 0.008</td><td>2.6</td><td>3.1 (2.3–3.5)<br/>p = 0.01</td><td>2.6</td></tr><tr><td></td><td colspan=\"2\">p<sub>interaction</sub> = 0.35</td><td colspan=\"2\">p<sub>interaction</sub> = 0.05</td><td></td></tr><tr><td><i>DRD2</i> rs6277 (cognitive flexibility)</td><td>0.9</td><td>1.8 (1.2–2.9)<br/>p = 0.01</td><td>1.9</td><td>1.5</td><td>1.6 (1.4–2.4)<br/>p = 0.03</td></tr><tr><td></td><td colspan=\"2\">p<sub>interaction</sub> = 0.013</td><td colspan=\"2\">p<sub>interaction</sub> = 0.72</td><td>p<sub>interaction</sub> = 0.32</td></tr></tbody></table>",
    "table_head": "<table><thead><tr><th></th><th>Females</th><th>Males</th><th>Hispanics</th><th>African American</th><th>Alcohol use</th></tr></thead><tbody><tr><td>DRD2 rs6277 (executive function)</td><td>1.3</td><td>3.5 (1.5–5.5)<br/>p = 0.008</td><td>2.6</td><td>3.1 (2.3–3.5)<br/>p = 0.01</td><td>2.6</td></tr><tr><td></td><td colspan=\"2\">p<sub>interaction</sub> = 0.35</td><td colspan=\"2\">p<sub>interaction</sub> = 0.05</td><td></td></tr><tr><td><i>DRD2</i> rs6277 (cognitive flexibility)</td><td>0.9</td><td>1.8 (1.2–2.9)<br/>p = 0.01</td><td>1.9</td><td>1.5</td><td>1.6 (1.4–2.4)<br/>p = 0.03</td></tr><tr><td></td><td colspan=\"2\">p<sub>interaction</sub> = 0.013</td><td colspan=\"2\">p<sub>interaction</sub> = 0.72</td><td>p<sub>interaction</sub> = 0.32</td></tr></tbody></table>",
    "caption": "DRD2 associations with cognitive flexibility and executive function in gender, race/ethnicity groups and alcohol use (ORs and 95% CIs)",
    "footnotes": [],
    "citations": [
      "Results of the analyses are presented in Tables 3 and 4. All SNPs were in Hardy–Weinberg equilibrium."
    ]
    },
    "PMC4794224_2": {
      "html_table": "<table><thead><tr><th><i>KIR</i> Genotypes</th><th>N (% Positive)</th></tr></thead><tbody><tr><td><i>KIR2DL1</i></td><td>966 (97%)</td></tr><tr><td><i>KIR2DL3</i></td><td>719 (72%)</td></tr><tr><td><i>KIR2DL4</i></td><td>993 (100%)</td></tr><tr><td><i>KIR2DL5</i></td><td>547 (55%)</td></tr><tr><td><i>KIR2DL2*004</i></td><td>31 (3%)</td></tr><tr><td><i>KIR2DL2*001/2/3/5</i></td><td>544 (55%)</td></tr><tr><td><i>KIR2DP1</i></td><td>964 (97%)</td></tr><tr><td><i>KIR2DS1</i></td><td>548 (55%)</td></tr><tr><td><i>KIR2DS2</i></td><td>581 (59%)</td></tr><tr><td><i>KIR2DS3</i></td><td>401 (40%)</td></tr><tr><td><i>KIR2DS4</i></td><td>993 (100%)</td></tr><tr><td><i>KIR2DS5</i></td><td>281 (28%)</td></tr><tr><td><i>KIR3DL1</i></td><td>929 (94%)</td></tr><tr><td><i>KIR3DL2</i></td><td>993 (100%)</td></tr><tr><td><i>KIR3DL3</i></td><td>993 (100%)</td></tr><tr><td><i>KIR3DS1</i></td><td>354 (36%)</td></tr></tbody></table>",
      "table_head": "<tr><th><i>KIR</i> Genotypes</th><th>N (% Positive)</th></tr>",
      "caption": "Frequency of <i>KIR</i> alleles.",
      "footnotes": [],
      "citations": ["Distribution of <i>KIR</i> alleles, centromeric (<i>Cent</i>), telomeric (<i>Tel</i>) and combined <i>Cent/Tel</i> alleles and combined <i>KIR/HLA</i> alleles in the studied cohort are listed in Tables 2, 3 and 4."]
    },
    "PMC6033411_2": {
      "html_table": "<table><thead><tr><th>Characteristic</th><th>Total number; N = 200<br/>N (%)</th><th>Clustered; N = 59<br/>N (%)</th><th>Odds ratio<br/>(95% CI)</th><th>P-value</th></tr></thead><tbody><tr><td><b>Age (years)</b></td><td></td><td></td><td></td><td></td></tr><tr><td><i>15 and younger</i></td><td>69 (34.5%)</td><td>22 (37.3%)</td><td>1.0 (ref)</td><td>…</td></tr><tr><td><i>16</i></td><td>46 (23%)</td><td>13 (22%)</td><td>0.84 (0.36–1.89)</td><td>0.67</td></tr><tr><td><i>17+</i></td><td>85 (42.5%)</td><td>24 (40.7%)</td><td>0.87 (0.43–1.76)</td><td>0.69</td></tr><tr><td><b>School grade</b></td><td></td><td></td><td></td><td></td></tr><tr><td><i>8–9</i></td><td>90 (45%)</td><td>30 (50.8%)</td><td>1.0 (ref)</td><td>…</td></tr><tr><td><i>10–12</i></td><td>110 (55%)</td><td>29 (49.2%)</td><td>0.8 (0.43–1.52)</td><td>0.5</td></tr><tr><td><b>Household income (R)</b></td><td></td><td></td><td></td><td></td></tr><tr><td><i>&lt;999</i></td><td>61 (30.5%)</td><td>22 (37.3%)</td><td>1.0 (ref)</td><td>…</td></tr><tr><td><i>10,000–99,000</i></td><td>112 (56%)</td><td>27 (45.8%)</td><td>0.56 (0.29–1.11)</td><td>0.1</td></tr><tr><td><i>&gt;100,000</i></td><td>27 (12.5%)</td><td>10 (16.9%)</td><td>1.04 (0.39–2.65)</td><td>0.93</td></tr><tr><td><b>CD4 cell count, cells/mm<sup>3</sup><sup>a</sup></b></td><td></td><td></td><td></td><td></td></tr><tr><td><i>&gt;500</i></td><td>92 (46%)</td><td>30 (50.9%)</td><td>1.0 (ref)</td><td>…</td></tr><tr><td><i>&le;500</i></td><td>75 (37.5%)</td><td>19 (32.2%)</td><td>0.70 (0.35–1.37)</td><td>0.31</td></tr><tr><td><i>&le;250</i></td><td>15 (7.5%)</td><td>4 (6.8%)</td><td>0.75 (0.2–2.4)</td><td>0.65</td></tr><tr><td><b>Major drug resistance mutation</b></td><td></td><td></td><td></td><td></td></tr><tr><td><i>No</i></td><td>180 (90%)</td><td>55 (93.2)</td><td>1.0 (ref)</td><td>…</td></tr><tr><td><i>Yes</i></td><td>20 (10%)</td><td>4 (6.8%)</td><td>0.57 (0.16–1.63)</td><td>0.33</td></tr><tr><td><b>HSV-2 infection<sup>b</sup></b></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>90 (45%)</td><td>25 (42.4%)</td><td>1.0 (ref)</td><td>…</td></tr><tr><td>Yes</td><td>69 (34.5%)</td><td>23 (39%)</td><td>1.3 (0.65–2.57)</td><td>0.45</td></tr><tr><td><b>Ever pregnant<sup>c</sup></b></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>122 (61%)</td><td>37 (62.7%)</td><td>1.0 (ref)</td><td>…</td></tr><tr><td>Yes</td><td>49 (24.5%)</td><td>15 (25.4%)</td><td>1.01 (0.48–2.06)</td><td>0.971</td></tr></tbody></table>",
      "table_head": "<tr><th>Characteristic</th><th>Total number; N = 200<br/>N (%)</th><th>Clustered; N = 59<br/>N (%)</th><th>Odds ratio<br/>(95% CI)</th><th>P-value</th></tr>",
      "caption": "Associations between demographic and epidemiological characteristics of 200 HIV-infected study participants and phylogenetic clustering (4.5% genetic distance threshold).",
      "footnotes": [
        "a CD4 cell count data was not available for 18 women",
        "b HSV-2 infection status was not available for 41 women",
        "c Pregnancy history was not available for 29 women.",
        "Abbreviations: N: number; CI: confidence intervals; ref: reference."
      ],
      "citations": [
        "Associations of demographic and clinical characteristics with HIV clustering are shown in Table 2. There was also no statistically significant excess co-clustering by study arm, drug resistance mutations detected, or any other study characteristic."
      ]
    },
    "PMC8748440_2": {
    "html_table": "<table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\"/><th align=\"left\">HR (95% CI for HR)</th><th align=\"left\">p value</th></tr></thead><tbody><tr><td align=\"left\">ISG15</td><td align=\"char\" char=\".\">0.29 (0.11\u20130.81)</td><td align=\"char\" char=\".\">0.0091</td></tr><tr><td align=\"left\">IFI6</td><td align=\"char\" char=\".\">0.18 (0.037\u20130.86)</td><td align=\"char\" char=\".\">0.014</td></tr><tr><td align=\"left\">IFI44L</td><td align=\"char\" char=\".\">0.55 (0.27\u20131.1)</td><td align=\"char\" char=\".\">0.083</td></tr><tr><td align=\"left\">IFI44</td><td align=\"char\" char=\".\">0.23 (0.047\u20131.2)</td><td align=\"char\" char=\".\">0.045</td></tr><tr><td align=\"left\">IFIT1</td><td align=\"char\" char=\".\">0.37 (0.12\u20131.1)</td><td align=\"char\" char=\".\">0.054</td></tr><tr><td align=\"left\">OAS3</td><td align=\"char\" char=\".\">0.52 (0.22\u20131.3)</td><td align=\"char\" char=\".\">0.15</td></tr><tr><td align=\"left\">XAF1</td><td align=\"char\" char=\".\">0.3 (0.1\u20130.92)</td><td align=\"char\" char=\".\">0.027</td></tr><tr><td align=\"left\">TRIM25</td><td align=\"char\" char=\".\">0.074 (0.0068\u20130.8)</td><td align=\"char\" char=\".\">0.023</td></tr><tr><td align=\"left\">CMPK2</td><td align=\"char\" char=\".\">0.23 (0.037\u20131.5)</td><td align=\"char\" char=\".\">0.074</td></tr><tr><td align=\"left\">RSAD2</td><td align=\"char\" char=\".\">0.2 (0.041\u20130.99)</td><td align=\"char\" char=\".\">0.032</td></tr><tr><td align=\"left\">EIF2AK2</td><td align=\"char\" char=\".\">0.54 (0.12\u20132.4)</td><td align=\"char\" char=\".\">0.42</td></tr><tr><td align=\"left\">USP18</td><td align=\"char\" char=\".\">0.23 (0.062\u20130.84)</td><td align=\"char\" char=\".\">0.022</td></tr><tr><td align=\"left\">HERC6</td><td align=\"char\" char=\".\">0.16 (0.019\u20131.3)</td><td align=\"char\" char=\".\">0.057</td></tr></tbody></table>",
    "table_head": "<table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\"/><th align=\"left\">HR (95% CI for HR)</th><th align=\"left\">p value</th></tr></thead><tbody><tr><td align=\"left\">ISG15</td><td align=\"char\" char=\".\">0.29 (0.11\u20130.81)</td><td align=\"char\" char=\".\">0.0091</td></tr><tr><td align=\"left\">IFI6</td><td align=\"char\" char=\".\">0.18 (0.037\u20130.86)</td><td align=\"char\" char=\".\">0.014</td></tr><tr><td align=\"left\">IFI44L</td><td align=\"char\" char=\".\">0.55 (0.27\u20131.1)</td><td align=\"char\" char=\".\">0.083</td></tr><tr><td align=\"left\">IFI44</td><td align=\"char\" char=\".\">0.23 (0.047\u20131.2)</td><td align=\"char\" char=\".\">0.045</td></tr><tr><td align=\"left\">IFIT1</td><td align=\"char\" char=\".\">0.37 (0.12\u20131.1)</td><td align=\"char\" char=\".\">0.054</td></tr><tr><td align=\"left\">OAS3</td><td align=\"char\" char=\".\">0.52 (0.22\u20131.3)</td><td align=\"char\" char=\".\">0.15</td></tr><tr><td align=\"left\">XAF1</td><td align=\"char\" char=\".\">0.3 (0.1\u20130.92)</td><td align=\"char\" char=\".\">0.027</td></tr><tr><td align=\"left\">TRIM25</td><td align=\"char\" char=\".\">0.074 (0.0068\u20130.8)</td><td align=\"char\" char=\".\">0.023</td></tr><tr><td align=\"left\">CMPK2</td><td align=\"char\" char=\".\">0.23 (0.037\u20131.5)</td><td align=\"char\" char=\".\">0.074</td></tr><tr><td align=\"left\">RSAD2</td><td align=\"char\" char=\".\">0.2 (0.041\u20130.99)</td><td align=\"char\" char=\".\">0.032</td></tr><tr><td align=\"left\">EIF2AK2</td><td align=\"char\" char=\".\">0.54 (0.12\u20132.4)</td><td align=\"char\" char=\".\">0.42</td></tr><tr><td align=\"left\">USP18</td><td align=\"char\" char=\".\">0.23 (0.062\u20130.84)</td><td align=\"char\" char=\".\">0.022</td></tr><tr><td align=\"left\">HERC6</td><td align=\"char\" char=\".\">0.16 (0.019\u20131.3)</td><td align=\"char\" char=\".\">0.057</td></tr></tbody></table>",
    "caption": "Univariable Cox regression for individual hub genes.",
    "footnotes": [
      "Hub genes identified by the WGCNA analysed contained within the \u2018salmon\u2019 Module 1. Genes in bold havep<\u20090.05 and were selected for the multivariable Cox/LASSO regression.HRhazard ratio,95% CI95% confidence intervals."
    ],
    "citations": [
      "As a next step, we looked to see if any of the individual hub genes identified in the WGCNA results were more closely linked to progression, potentially leading to a signature that might predict longer post-TI viral suppression. Univariable analysis showed that the expression of 7 out of 13 hub genes contained in Module 1 (ISG15, IFI6, IFI44, RSAD2, XAF1, USP18andTRIM25)were significantly associated with a protective Hazard Ratio (HR) for viral rebound (Table2). A multivariable Cox Regression analysis was performed including these seven genes. Least Absolute Shrinkage and Selection Operator (LASSO) was used to eliminate genes with zero coefficients (IFI6, IFI44andRSAD2) and only four genes (ISG15; cor\u2009=\u2009-0.41,TRIM25; cor\u2009=\u20140.32,XAF1; cor\u2009=\u2009-0.06 andUSP18; cor\u2009=\u2009-0.14) were retained (Supplementary TableS1).Table 2Univariable Cox regression for individual hub genes.HR (95% CI for HR)pvalueISG150.29 (0.11\u20130.81)0.0091IFI60.18 (0.037\u20130.86)0.014IFI44L0.55 (0.27\u20131.1)0.083IFI440.23 (0.047\u20131.2)0.045IFIT10.37 (0.12\u20131.1)0.054OAS30.52 (0.22\u20131.3)0.15XAF10.3 (0.1\u20130.92)0.027TRIM250.074 (0.0068\u20130.8)0.023CMPK20.23 (0.037\u20131.5)0.074RSAD20.2 (0.041\u20130.99)0.032EIF2AK20.54 (0.12\u20132.4)0.42USP180.23 (0.062\u20130.84)0.022HERC60.16 (0.019\u20131.3)0.057Hub genes identified by the WGCNA analysed contained within the \u2018salmon\u2019 Module 1. Genes in bold havep<\u20090.05 and were selected for the multivariable Cox/LASSO regression.HRhazard ratio,95% CI95% confidence intervals."
    ]
    },
    "PMC7644038_3": {
      "html_table": "<table frame=\"hsides\" rules=\"groups\">\n  <colgroup span=\"1\">\n    <col align=\"left\" valign=\"middle\" span=\"1\"/>\n    <col align=\"left\" valign=\"middle\" span=\"1\"/>\n    <col align=\"left\" valign=\"middle\" span=\"1\"/>\n    <col align=\"left\" valign=\"middle\" span=\"1\"/>\n    <col align=\"left\" valign=\"middle\" span=\"1\"/>\n  </colgroup>\n  <thead>\n    <tr>\n      <th align=\"left\"></th>\n      <th align=\"center\" colspan=\"3\">Medicare beneficiaries at age 65 between 2011–2016, unadjusted</th>\n      <th align=\"center\">Coefficients from logistic regression model, odds ratios reported (Medicare beneficiaries aged 65 and above in 2016)<sup>a</sup></th>\n    </tr>\n    <tr>\n      <th></th>\n      <th align=\"center\">(1)</th>\n      <th align=\"center\">(2)</th>\n      <th align=\"center\">(3)</th>\n      <th align=\"center\">(4)</th>\n    </tr>\n    <tr>\n      <th></th>\n      <th align=\"center\">HIV</th>\n      <th align=\"center\">No HIV</th>\n      <th align=\"center\">Percent difference</th>\n      <th align=\"center\">HIV</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <td align=\"left\">Depression</td>\n      <td align=\"center\">24.3%</td>\n      <td align=\"center\">6.2%</td>\n      <td align=\"center\">291.9%***</td>\n      <td align=\"center\">2.29*** [2.22, 2.35]</td>\n    </tr>\n    <tr>\n      <td align=\"left\">Chronic kidney disease</td>\n      <td align=\"center\">46.2%</td>\n      <td align=\"center\">18.9%</td>\n      <td align=\"center\">144.4%***</td>\n      <td align=\"center\">1.92*** [1.88, 1.97]</td>\n    </tr>\n  </tbody>\n</table>",
      "table_head": "<thead>\n  <tr>\n    <th align=\"left\"></th>\n    <th align=\"center\" colspan=\"3\">Medicare beneficiaries at age 65 between 2011–2016, unadjusted</th>\n    <th align=\"center\">Coefficients from logistic regression model, odds ratios reported (Medicare beneficiaries aged 65 and above in 2016)<sup>a</sup></th>\n  </tr>\n  <tr>\n    <th></th>\n    <th align=\"center\">(1)</th>\n    <th align=\"center\">(2)</th>\n    <th align=\"center\">(3)</th>\n    <th align=\"center\">(4)</th>\n  </tr>\n  <tr>\n    <th></th>\n    <th align=\"center\">HIV</th>\n    <th align=\"center\">No HIV</th>\n    <th align=\"center\">Percent difference</th>\n    <th align=\"center\">HIV</th>\n  </tr>\n</thead>\n<tbody>\n  <tr>\n    <td align=\"left\">Depression</td>\n    <td align=\"center\">24.3%</td>\n    <td align=\"center\">6.2%</td>\n    <td align=\"center\">291.9%***</td>\n    <td align=\"center\">2.29*** [2.22, 2.35]</td>\n  </tr>\n  <tr>\n    <td align=\"left\">Chronic kidney disease</td>\n    <td align=\"center\">46.2%</td>\n    <td align=\"center\">18.9%</td>\n    <td align=\"center\">144.4%***</td>\n    <td align=\"center\">1.92*** [1.88, 1.97]</td>\n  </tr>\n</tbody>",
      "caption": "Prevalence of health outcomes, unadjusted means and odds ratios reported.",
      "footnotes": [
        "Each individual appears in this table once; in columns one through three it is at age 65, in column 4 it is in 2016 (in which upper age is trimmed at 98 years to avoid the impact of outliers who predominantly do not have HIV). Significance of the differences between (1) and (2) were calculated for each row using a chi-squared test. Not shown are controls for age, race/ethnicity, sex, state, rural/urban residence, and dual enrollment in Medicaid. The omitted group is White, urban, non-Medicaid enrolled males between the age of 65 and 74. Individuals are weighted using probability weights to reflect differential selection probabilities based on HIV diagnosis. 95% confidence intervals are reported in parentheses. Significance levels are shown with *** p-value<0.001, ** p-value < 0.01, and * p-value < 0.05.",
        "Each cell in (4) is a coefficient from a different model. Significance levels have been adjusted using the Bonferroni correction for multiple hypothesis testing to reflect 11 tests."
      ],
      "citations": [
        "People with HIV had higher overall unadjusted rates for all health conditions compared to those without diagnosed HIV (Columns 1 through 3 in Table 3)."
      ]
    },
    "PMC7414801_2": {
      "html_table": "<table frame=\"hsides\" rules=\"groups\">\n  <colgroup>\n    <col align=\"left\"/>\n    <col align=\"center\"/>\n    <col align=\"center\"/>\n    <col align=\"center\"/>\n    <col align=\"center\"/>\n    <col align=\"center\"/>\n    <col align=\"center\"/>\n  </colgroup>\n  <thead>\n    <tr>\n      <th align=\"left\"> </th>\n      <th align=\"center\">HIV detection visit</th>\n      <th align=\"center\">M3,<italic> n </italic>(%)</th>\n      <th align=\"center\">M6,<italic> n </italic>(%)</th>\n      <th align=\"center\">M9,<italic> n </italic>(%)</th>\n      <th align=\"center\">M12,<italic> n </italic>(%)</th>\n      <th align=\"center\">M15,<italic> n </italic>(%)</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <td colspan=\"7\" align=\"left\">As-randomized (<italic>n</italic> = 382)<sup>a</sup></td>\n    </tr>\n    <tr>\n      <td align=\"left\">HIV VL</td>\n      <td align=\"center\">381 (100)</td>\n      <td align=\"center\">114 (30)</td>\n      <td align=\"center\">73 (19)</td>\n      <td align=\"center\">43 (11)</td>\n      <td align=\"center\">26 (7)</td>\n      <td align=\"center\">17 (4)</td>\n    </tr>\n    <tr>\n      <td align=\"left\">CD4</td>\n      <td align=\"center\">382 (100)</td>\n      <td align=\"center\">115 (30)</td>\n      <td align=\"center\">73 (19)</td>\n      <td align=\"center\">44 (12)</td>\n      <td align=\"center\">26 (7)</td>\n      <td align=\"center\">17 (4)</td>\n    </tr>\n    <tr>\n      <td colspan=\"7\" align=\"left\">Continuous use (<italic>n</italic> = 331)</td>\n    </tr>\n    <tr>\n      <td align=\"left\">HIV VL</td>\n      <td align=\"center\">330 (100)</td>\n      <td align=\"center\">99 (30)</td>\n      <td align=\"center\">65 (20)</td>\n      <td align=\"center\">40 (12)</td>\n      <td align=\"center\">25 (8)</td>\n      <td align=\"center\">14 (4)</td>\n    </tr>\n    <tr>\n      <td align=\"left\">CD4</td>\n      <td align=\"center\">331 (100)</td>\n      <td align=\"center\">99 (30)</td>\n      <td align=\"center\">64 (19)</td>\n      <td align=\"center\">40 (12)</td>\n      <td align=\"center\">25 (8)</td>\n      <td align=\"center\">14 (4)</td>\n    </tr>\n  </tbody>\n</table>",
      "table_head": "<thead>\n  <tr>\n    <th align=\"left\"> </th>\n    <th align=\"center\">HIV detection visit</th>\n    <th align=\"center\">M3,<italic> n </italic>(%)</th>\n    <th align=\"center\">M6,<italic> n </italic>(%)</th>\n    <th align=\"center\">M9,<italic> n </italic>(%)</th>\n    <th align=\"center\">M12,<italic> n </italic>(%)</th>\n    <th align=\"center\">M15,<italic> n </italic>(%)</th>\n  </tr>\n</thead>\n<tbody>\n  <tr>\n    <td colspan=\"7\" align=\"left\">As-randomized (<italic>n</italic> = 382)<sup>a</sup></td>\n  </tr>\n  <tr>\n    <td align=\"left\">HIV VL</td>\n    <td align=\"center\">381 (100)</td>\n    <td align=\"center\">114 (30)</td>\n    <td align=\"center\">73 (19)</td>\n    <td align=\"center\">43 (11)</td>\n    <td align=\"center\">26 (7)</td>\n    <td align=\"center\">17 (4)</td>\n  </tr>\n</tbody>",
      "caption": "Summary of HIV Seroconverter Data Available by Months Since HIV Detection Visit",
      "footnotes": [
        "Excludes women infected at baseline and visits following ART initiation."
      ],
      "citations": [
        "Among the 382 participants in the as-randomized analysis, 331 contributed to the continuous use analysis (80%, 87%, and 94% of DMPA-IM, copper IUD, and LNG implant users, respectively) (Table 2)."
      ]
    },
    "PMC8340029_2": {
      "html_table": "<table><thead><tr><th></th><th align=\"left\">Number of infections/person-years</th><th align=\"left\">Incidence</th><th align=\"left\">Adjusted incidence rate ratio (95% CI)</th><th align=\"left\">p value</th><th align=\"left\">Adjusted incidence rate ratio (95% CI)</th><th align=\"left\">p value</th></tr></thead><tbody><tr><td colspan=\"7\" align=\"left\"><b>Including study visits with on-site PrEP access</b></td></tr><tr><td align=\"left\">Before access</td><td align=\"left\">133/2860</td><td align=\"left\">4·65%</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td></tr><tr><td align=\"left\">After access</td><td align=\"left\">12/556</td><td align=\"left\">2·16%</td><td align=\"left\">0·45 (0·25-0·81)</td><td align=\"left\">0·0076</td><td align=\"left\">0·45 (0·25-0·82)</td><td align=\"left\">0·0085</td></tr><tr><td colspan=\"7\" align=\"left\"><b>180 days before versus 180 days after on-site PrEP access</b></td></tr><tr><td align=\"left\">Before access</td><td align=\"left\">46/919</td><td align=\"left\">5·00%</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td></tr><tr><td align=\"left\">After access</td><td align=\"left\">11/481</td><td align=\"left\">2·29%</td><td align=\"left\">0·44 (0·23-0·85)</td><td align=\"left\">0·015</td><td align=\"left\">0·43 (0·22-0·83)</td><td align=\"left\">0·012</td></tr></tbody></table>",
      "table_head": "<thead><tr><th></th><th align=\"left\">Number of infections/person-years</th><th align=\"left\">Incidence</th><th align=\"left\">Adjusted incidence rate ratio (95% CI)</th><th align=\"left\">p value</th><th align=\"left\">Adjusted incidence rate ratio (95% CI)</th><th align=\"left\">p value</th></tr></thead><tbody><tr><td colspan=\"7\" align=\"left\"><b>Including study visits with on-site PrEP access</b></td></tr><tr><td align=\"left\">Before access</td><td align=\"left\">133/2860</td><td align=\"left\">4·65%</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td></tr>",
      "caption": "Effect of on-site PrEP access on HIV incidence",
      "footnotes": [
        "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis.",
        "Adjusted for study site and randomisation group.",
        "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
      ],
      "citations": [
        "A total of 133 HIV seroconversions were observed in 2860 person-years (4·65 per 100 person-years) before PrEP access, compared with 12 HIV seroconversions in 556 person-years (incidence 2·16 per 100 person-years) after PrEP access (adjusted IRR 0·45, 95% CI 0·25–0·82, p=0·0085; table 2)."
      ]
    },
    "PMC8391097_3": {
      "html_table": "<table frame=\"hsides\" rules=\"groups\">\n  <thead>\n    <tr>\n      <th>PrEP status</th>\n      <th>HIV infections, No./total No. of individuals</th>\n      <th>Total follow-up, person-years</th>\n      <th>Incidence (95% CI), per 100 person-years</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <td>Overall<sup>a</sup></td>\n      <td>91/13 861</td>\n      <td>26 210</td>\n      <td>0.35 (0.28-0.43)</td>\n    </tr>\n    <tr>\n      <td>Linked but not prescribed PrEP</td>\n      <td>36/3013</td>\n      <td>4119</td>\n      <td>0.87 (0.63-1.21)</td>\n    </tr>\n    <tr>\n      <td>Prescribed PrEP but did not initiate</td>\n      <td>13/811</td>\n      <td>1226</td>\n      <td>1.06 (0.62-1.83)</td>\n    </tr>\n    <tr>\n      <td>Discontinued but reinitiated PrEP</td>\n      <td>4/1082</td>\n      <td>1420</td>\n      <td>0.28 (0.11-0.75)</td>\n    </tr>\n    <tr>\n      <td>Discontinued and did not reinitiate PrEP</td>\n      <td>38/2108</td>\n      <td>2973</td>\n      <td>1.28 (0.93-1.76)</td>\n    </tr>\n    <tr>\n      <td>Persistent on PrEP<sup>b</sup></td>\n      <td>0/5367</td>\n      <td>9139</td>\n      <td>0.00 (0.00-0.04)<sup>c</sup></td>\n    </tr>\n  </tbody>\n</table>",
      "table_head": "<table>\n  <thead>\n    <tr>\n      <th>PrEP status</th>\n      <th>HIV infections, No./total No. of individuals</th>\n      <th>Total follow-up, person-years</th>\n      <th>Incidence (95% CI), per 100 person-years</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <td>Overall<sup>a</sup></td>\n      <td>91/13 861</td>\n      <td>26 210</td>\n      <td>0.35 (0.28-0.43)</td>\n    </tr>\n    <tr>\n      <td>Linked but not prescribed PrEP</td>\n      <td>36/3013</td>\n      <td>4119</td>\n      <td>0.87 (0.63-1.21)</td>\n    </tr>\n  </tbody>\n</table>",
      "caption": "HIV Incidence Rate Estimates",
      "footnotes": [
        "a: Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage.",
        "b: Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up.",
        "c: One-sided 97.5% upper CI."
      ],
      "citations": [
        "Excluding patients who were diagnosed at linkage, the overall HIV incidence rate was 0.35 (95% CI, 0.28-0.43) new infections per 100 person-years, 0.87 (95% CI, 0.63-1.21) among those not prescribed PrEP, 1.06 (95% CI, 0.62-1.83) among those prescribed but not initiated, and 1.28 (95% CI, 0.93-1.76) among those who discontinued and did not reinitiate PrEP (Table 3)."
      ]
    },
    "PMC8668943_3": {
      "html_table": "<table><thead><tr><th><i>FcγRIIc</i> copy number (Total group)</th><th>Univariate OR (95% CI)</th><th>P-value</th><th>Adjusted OR</th><th>P-value</th></tr></thead><tbody><tr><td>1 copy</td><td>0.29 (0.12-0.71)</td><td><b>0.007</b> (<i>P</i><sub>Bonf</sub> = 0.112)</td><td>0.37 (0.15-0.90)</td><td><b>0.029</b> (<i>P</i><sub>Bonf</sub> = 0.464)</td></tr><tr><td>2 copies</td><td>Ref</td><td></td><td>Ref</td><td></td></tr><tr><td>≥3 copies</td><td>0.99 (0.63-1.57)</td><td>0.978</td><td>0.74 (0.43-1.27)</td><td>0.275</td></tr></tbody></table>",
      "table_head": "<thead><tr><th><i>FcγRIIc</i> copy number (Total group)</th><th>Univariate OR (95% CI)</th><th>P-value</th><th>Adjusted OR</th><th>P-value</th></tr></thead><tbody><tr><td>1 copy</td><td>0.29 (0.12-0.71)</td><td><b>0.007</b> (<i>P</i><sub>Bonf</sub> = 0.112)</td><td>0.37 (0.15-0.90)</td><td><b>0.029</b> (<i>P</i><sub>Bonf</sub> = 0.464)</td></tr><tr><td>2 copies</td><td>Ref</td><td></td><td>Ref</td><td></td></tr>",
      "caption": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition, adjusting for birthweight and FCGR2C genotypes.",
      "footnotes": [
        "OR, Odds Ratio; CI, Confidence Interval; PBonf, Bonferroni corrected P value.",
        "Bold indicates statistical significance of P < 0.05."
      ],
      "citations": [
        "Using two FCGR2C gene copies as reference, the possession of a single gene copy was independently associated with reduced odds of HIV-1 acquisition (OR = 0.29; 95% CI 0.12-0.71; P = 0.007, PBonf > 0.05) and retained significance after controlling for birthweight and FCGR2C genotypes (AOR = 0.37; 95% CI 0.15-0.90; P = 0.029, PBonf > 0.05) (Table 3)."
      ]

      
    },
    "PMC6694514_3": {
      "html_table": "<table frame=\"hsides\" rules=\"groups\">\n  <thead>\n    <tr>\n      <th>Adverse Event SOC</th>\n      <th>HIV-positive Patients (% of G3+ Events)</th>\n      <th>HIV-negative Patients (% of G3+ Events)</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <td>Hepatobiliary disorders</td>\n      <td>12 (30.0%)</td>\n      <td>15 (25.0%)</td>\n    </tr>\n    <tr>\n      <td>Respiratory and thoracic disorders</td>\n      <td>7 (17.5%)</td>\n      <td>13 (21.7%)</td>\n    </tr>\n    <tr>\n      <td>Blood and lymphatic disorders</td>\n      <td>6 (15.0%)</td>\n      <td>10 (16.7%)</td>\n    </tr>\n    <tr>\n      <td>Infections and infestations</td>\n      <td>3 (7.5%)</td>\n      <td>5 (8.3%)</td>\n    </tr>\n    <tr>\n      <td>Metabolism and nutrition disorders</td>\n      <td>3 (7.5%)</td>\n      <td>4 (6.7%)</td>\n    </tr>\n    <tr>\n      <td>Other</td>\n      <td>9 (17.5%)</td>\n      <td>13 (16.7%)</td>\n    </tr>\n  </tbody>\n</table>",
      "table_head": "<thead>\n  <tr>\n    <th>Adverse Event SOC</th>\n    <th>HIV-positive Patients (% of G3+ Events)</th>\n    <th>HIV-negative Patients (% of G3+ Events)</th>\n  </tr>\n</thead>\n<tbody>\n  <tr>\n    <td>Hepatobiliary disorders</td>\n    <td>12 (30.0%)</td>\n    <td>15 (25.0%)</td>\n  </tr>\n  <tr>\n    <td>Respiratory and thoracic disorders</td>\n    <td>7 (17.5%)</td>\n    <td>13 (21.7%)</td>\n  </tr>",
      "caption": "System Organ Classes (SOCs) for the five most frequently reported grade 3 or 4 Adverse Events (AEs) reported by HIV-positive and HIV-negative patients in the matched population during enrolment in the REMoxTB trial. Total number of grade 3 or 4 adverse events of the SOC shown according to HIV status and percentage of total number of grade 3 or 4 AEs in HIV group provided in brackets",
      "footnotes": [],
      "citations": [
        "A total of 20 of the 42 (47.6%) HIV-positive patients experienced ≥1 grade 3 or 4 AE, as opposed to 34 of the 220 (15.5%) HIV-negative patients. One or more grade 3 or 4 AE considered to be at least possibly related to treatment was reported by 11 of 42 (26.2%) HIV positive patients and 14 of 220 (6.4%) HIV-negative patients. The majority of these were hepatobiliary disorders that accounted for 12 of 40 (30.0%) events occurring in 6 of 42 (14.3%) HIV-positive patients and for 15 of 60 (25.0%) events occurring in 9 of 220 (4.1%) HIV-negative patients (see Table 3)."
      ]
    },
    "PMC5817808_2": {
      "html_table": "<table frame=\"hsides\" rules=\"groups\">\n  <thead>\n    <tr>\n      <th></th>\n      <th>Unadjusted HR</th>\n      <th><i>p</i>-value</th>\n      <th>Adjusted HR</th>\n      <th><i>p</i>-value</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr><td colspan=\"5\">Mode of feeding</td></tr>\n    <tr>\n      <td> Exclusive breast feeding</td>\n      <td>1.35 [0.52-3.49]</td>\n      <td>0.54</td>\n      <td>1.16 [0.44-3.08]</td>\n      <td>0.76</td>\n    </tr>\n    <tr>\n      <td> Mixed feeding</td>\n      <td>0.31 [0.04-2.42]</td>\n      <td>0.26</td>\n      <td>0.44 [0.053-3.74]</td>\n      <td>0.45</td>\n    </tr>\n    <tr>\n      <td> Exclusive replacement feeding</td>\n      <td>Ref</td>\n      <td>Ref</td>\n      <td>Ref</td>\n      <td>Ref</td>\n    </tr>\n    <tr><td colspan=\"5\">HIV- Status</td></tr>\n    <tr>\n      <td> Positive</td>\n      <td>0.31 [0.11-0.90]</td>\n      <td>0.032</td>\n      <td>0.30 [0.08-1.11]</td>\n      <td>0.071</td>\n    </tr>\n    <tr>\n      <td> Negative</td>\n      <td>Ref</td>\n      <td>Ref</td>\n      <td>Ref</td>\n      <td>Ref</td>\n    </tr>\n    <tr><td colspan=\"5\">Birth weight</td></tr>\n    <tr>\n      <td> &gt;=2500 g</td>\n      <td>0.88 [0.34-2.28]</td>\n      <td>0.80</td>\n      <td>0.93 [0.21-4.12]</td>\n      <td>0.92</td>\n    </tr>\n    <tr>\n      <td> &lt;2500 g</td>\n      <td>Ref</td>\n      <td>Ref</td>\n      <td>Ref</td>\n      <td>Ref</td>\n    </tr>\n    <tr>\n      <td>Global Schoenfeld residuals test</td>\n      <td></td>\n      <td></td>\n      <td></td>\n      <td>0.23</td>\n    </tr>\n  </tbody>\n</table>",
      "table_head": "<thead>\n  <tr>\n    <th></th>\n    <th>Unadjusted HR</th>\n    <th><i>p</i>-value</th>\n    <th>Adjusted HR</th>\n    <th><i>p</i>-value</th>\n  </tr>\n</thead>\n<tbody>\n  <tr><td colspan=\"5\">Mode of feeding</td></tr>\n  <tr>\n    <td> Exclusive breast feeding</td>\n    <td>1.35 [0.52-3.49]</td>\n    <td>0.54</td>\n    <td>1.16 [0.44-3.08]</td>\n    <td>0.76</td>\n  </tr>",
      "caption": "Unadjusted and adjusted Hazard Ratio (HRs) of survival at 24 months in the HIV exposed infants of the Essos hospital center PMTCT program",
      "footnotes": [],
      "citations": [
        "Overall infant mortality in the study population was 2.58% (28), with varying trends according to feeding option: ERF (2.41%), EBF (2.45%), MF (13.33%), p = 0.032 (Table 2), indicating an increment of 5.4 and 5.5 folds in mortality for MF infants compared to EBF and ERF respectively."
      ]
    },
    "PMC6937831_2": {
      "html_table": "<table frame=\"hsides\" rules=\"groups\">\n  <thead>\n    <tr>\n      <th rowspan=\"2\"></th>\n      <th colspan=\"5\">Non-AIDS-Related Death (NARD)</th>\n      <th colspan=\"3\">AIDS-Related Death (ARD)</th>\n    </tr>\n    <tr>\n      <th>Cancer</th>\n      <th>Other diseases</th>\n      <th>CVD</th>\n      <th>Hepatic/liver-related</th>\n      <th>External death</th>\n      <th>Other diseases</th>\n      <th>Cancer</th>\n      <th>Opportunistic</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <td>Number of deaths</td>\n      <td>6 (4%)</td>\n      <td>10 (8%)</td>\n      <td>12 (9%)</td>\n      <td>34 (24%)</td>\n      <td>78 (55%)</td>\n      <td>2 (1%)</td>\n      <td>8 (3%)</td>\n      <td>241 (96%)</td>\n    </tr>\n  </tbody>\n</table>",
      "table_head": "<thead>\n  <tr>\n    <th rowspan=\"2\"></th>\n    <th colspan=\"5\">Non-AIDS-Related Death (NARD)</th>\n    <th colspan=\"3\">AIDS-Related Death (ARD)</th>\n  </tr>\n  <tr>\n    <th>Cancer</th>\n    <th>Other diseases</th>\n    <th>CVD</th>\n    <th>Hepatic/liver-related</th>\n    <th>External death</th>\n    <th>Other diseases</th>\n    <th>Cancer</th>\n    <th>Opportunistic</th>\n  </tr>\n</thead>\n<tbody>\n  <tr>\n    <td>Number of deaths</td>\n    <td>6 (4%)</td>\n    <td>10 (8%)</td>\n    <td>12 (9%)</td>\n    <td>34 (24%)</td>\n    <td>78 (55%)</td>\n    <td>2 (1%)</td>\n    <td>8 (3%)</td>\n    <td>241 (96%)</td>\n  </tr>\n</tbody>",
      "caption": "Death category of individuals living with HIV",
      "footnotes": [
        "External death: Sudden death, including accident, overdose, and suicide",
        "Other diseases: Unknown death categorized based on CD4 count within 6-months prior to the date of death. The CD4 cell count of lower than 200 cells/mm² was categorized as ARM and otherwise as NARM",
        "Cancer: Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
      ],
      "citations": [
        "Moreover, 14 deaths (7%) were related to cancer as shown in Table 2."
      ]
    },
    "PMC9077443_2": {
    "html_table": "<table frame=\"hsides\" rules=\"groups\"><thead><tr><th></th><th></th><th align=\"left\">Events per total PY in cabotegravir group</th><th align=\"left\">Events per total PY in TDF-FTC group</th><th align=\"left\">HR (95% CI)</th><th align=\"left\">p value</th></tr></thead><tbody><tr><td colspan=\"2\" align=\"left\">Overall</td><td align=\"left\">4/1956 (0·20%)</td><td align=\"left\">36/1942 (1·85%)</td><td align=\"left\">0·12 (0·05–0·31)</td><td align=\"left\"><0·0001</td></tr><tr><td colspan=\"2\" align=\"left\">Age</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">0·53</td></tr><tr><td></td><td align=\"left\"><25 years</td><td align=\"left\">3/866 (0·35%)</td><td align=\"left\">20/851 (2·34%)</td><td align=\"left\">0·17 (0·05–0·54)</td><td align=\"left\">.</td></tr><tr><td></td><td align=\"left\">≥25 years</td><td align=\"left\">1/1090 (0·09%)</td><td align=\"left\">16/1091 (1·47%)</td><td align=\"left\">0·09 (0·02–0·49)</td><td align=\"left\">.</td></tr><tr><td colspan=\"2\" align=\"left\">Contraceptive method</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">0·87</td></tr><tr><td></td><td align=\"left\">DMPA</td><td align=\"left\">3/1009 (0·30%)</td><td align=\"left\">21/1000 (2·10%)</td><td align=\"left\">0·16 (0·05–0·53)</td><td align=\"left\">.</td></tr><tr><td></td><td align=\"left\">NET-EN</td><td align=\"left\">1/175 (0·57%)</td><td align=\"left\">6/182 (3·30%)</td><td align=\"left\">0·22 (0·03–1·48)</td><td align=\"left\">.</td></tr><tr><td></td><td align=\"left\">Implant</td><td align=\"left\">0</td><td align=\"left\">8/607 (1·32%)</td><td align=\"left\">0·06 (0·00–1·16)</td><td align=\"left\">.</td></tr><tr><td></td><td align=\"left\">Other</td><td align=\"left\">0</td><td align=\"left\">1/152 (0·66%)</td><td align=\"left\">0·32 (0·01–9·89)</td><td align=\"left\">.</td></tr><tr><td colspan=\"2\" align=\"left\">Body-mass index</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td></tr><tr><td></td><td align=\"left\">≤30 kg/m<sup>2</sup></td><td align=\"left\">4/1389 (0·29%)</td><td align=\"left\">27/1447 (1·87%)</td><td align=\"left\">0·16 (0·06–0·45)</td><td align=\"left\">0·47</td></tr><tr><td></td><td align=\"left\">>30 kg/m<sup>2</sup></td><td align=\"left\">0</td><td align=\"left\">9/495 (1·82%)</td><td align=\"left\">0·05 (0·00–0·96)</td><td align=\"left\">.</td></tr></tbody></table>",
    "table_head": "<thead><tr><th></th><th></th><th align=\"left\">Events per total PY in cabotegravir group</th><th align=\"left\">Events per total PY in TDF-FTC group</th><th align=\"left\">HR (95% CI)</th><th align=\"left\">p value</th></tr></thead><tbody><tr><td colspan=\"2\" align=\"left\">Overall</td><td align=\"left\">4/1956 (0·20%)</td><td align=\"left\">36/1942 (1·85%)</td><td align=\"left\">0·12 (0·05–0·31)</td><td align=\"left\"><0·0001</td></tr><tr><td colspan=\"2\" align=\"left\">Age</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">.</td><td align=\"left\">0·53</td></tr></tbody>",
    "caption": "Cabotegravir effectiveness, overall and by subgroup",
    "footnotes": [
      "HR=hazard ratio. PY=person-years. TDF-FTC=tenofovir disoproxil fumarate plus emtricitabine. DMPA=depot medroxyprogesterone acetate. NET-EN=norethisterone enanthate.",
      "* Firth's method was used to estimate the HR and 95% CI when the subgroup had zero infections (used for subgroup analysis only, stratified by site).",
      "† Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed."
    ],
    "citations": [
      "40 HIV infections met the primary endpoint definition and were included in the ITT analysis. Four HIV infections were observed in the cabotegravir group (HIV incidence 0·20 per 100 person-years [95% CI 0·06–0·52]) and 36 in the TDF-FTC group (1·85 per 100 person-years [1·3–2·57]; table 2)."
    ]
    },
    "PMC7615197_2": {
      "html_table": "<table frame=\"box\" rules=\"cols\"><thead><tr><th rowspan=\"2\"> </th><th colspan=\"2\">No. of deaths</th><th rowspan=\"2\">Hazard ratio (95% CI); P value</th><th rowspan=\"2\">Test for proportional hazards</th><th rowspan=\"2\">P-value for heterogeneity*</th></tr><tr><th>Dexamethasone (N=263)</th><th>Placebo (N=257)</th></tr></thead><tbody><tr><td>Intention-to-treat population</td><td>116/263</td><td>126/257</td><td>0.85 (0.66, 1.10); P=0.22</td><td>0.36</td><td></td></tr><tr><td>Modified MRC grade:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- Grade I</td><td>22/99</td><td>28/97</td><td>0.72 (0.41, 1.25); P=0.24</td><td>0.15</td><td rowspan=\"3\">0.63</td></tr><tr><td>- Grade II</td><td>60/125</td><td>68/126</td><td>0.82 (0.58, 1.16); P=0.27</td><td>0.57</td></tr><tr><td>- Grade III</td><td>34/39</td><td>30/34</td><td>1.11 (0.70, 1.77); P=0.65</td><td>0.89</td></tr></tbody></table>",
      "table_head": "<thead><tr><th rowspan=\"2\"> </th><th colspan=\"2\">No. of deaths</th><th rowspan=\"2\">Hazard ratio (95% CI); P value</th><th rowspan=\"2\">Test for proportional hazards</th><th rowspan=\"2\">P-value for heterogeneity*</th></tr><tr><th>Dexamethasone (N=263)</th><th>Placebo (N=257)</th></tr></thead><tbody><tr><td>Intention-to-treat population</td><td>116/263</td><td>126/257</td><td>0.85 (0.66, 1.10); P=0.22</td><td>0.36</td><td></td></tr><tr><td>Modified MRC grade:</td><td></td><td></td><td></td><td></td><td></td></tr></tbody>",
      "caption": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
      "footnotes": [
        "Heterogeneity was tested by a Cox regression model that includes an interaction between treatment effect and subgroup.",
        "Rationale for Leukotriene A4 hydrolase genotype sub-group provided in Supplementary Text S6.",
        "Results are given for a sub-group with positive mycobacterial culture on baseline cerebrospinal fluid. The primary endpoint was death from any cause over the first 12 months after randomization, i.e., time from randomization to death, over the first 12 months of follow-up. This table reports the results from the Cox proportional hazards regression model. The primary effect measure was the resulting hazard ratio comparing dexamethasone vs. placebo with a corresponding two-sided 95% confidence interval. In the ‘Intention-to-treat population’, treatment was the only covariate. We additionally report the hazard ratio with the modified MRC grade included as stratum variable. The test for proportional hazards used the Kaplan-Meier as time transformation. In subgroup analyses, a separate Cox model was fitted for each value of the subgroup. The test for heterogeneity was based on the likelihood ratio test that includes subgroup as covariate and compares the models with subgroup as main effect only and with subgroup as treatment effect modifier, with TBM MRC severity grade at enrolment (I, II, or III) as covariates. ART=antiretroviral therapy. MRC=Medical Research Council. MDR=multi-drug resistant. TBM=tuberculous meningitis."
      ],
      "citations": [
        "There were 116/263 (44.1%) observed deaths in the dexamethasone arm and 126/257 (49.0%) deaths in the placebo arm (HR 0.85, 95% confidence interval [CI] 0.66-1.10; P=0.22) (Table 2). Similar results were observed when adjusted for MRC severity grade. Heterogeneity of effect was not observed by any pre-specified sub-group in the intention-to-treat (Table 2) and the per-protocol populations."
      ]
    },
    "PMC10294491_2": {
      "html_table": "<table frame=\"hsides\" rules=\"groups\"><tbody><tr><td colspan=\"6\">Original analysis on rate ratio scale</td></tr><tr><td>Group</td><td>No. subjects</td><td>PYFU</td><td>Incident HIV infections</td><td>Incidence rate (per 100 PYFU)</td><td>Rate ratio (95% CI)</td></tr><tr><td>TDF/FTC</td><td>2693</td><td>4386</td><td>11</td><td>0.251</td><td>REF</td></tr><tr><td>TAF/FTC</td><td>2694</td><td>4370</td><td>6</td><td>0.137</td><td>0.55 (0.20, 1.48)</td></tr><tr><td colspan=\"6\">Re-analysis using an averted infections framework</td></tr><tr><td>Group</td><td>PYFU</td><td>Observed infections</td><td>Predicted infections<sup>a</sup></td><td>Averted infections</td><td>Averted infections ratio (95% CI)</td></tr><tr><td>TDF/FTC</td><td>4386</td><td>11</td><td>90.4</td><td>79.4</td><td>REF</td></tr><tr><td>TAF/FTC</td><td>4370</td><td>6</td><td>90.0</td><td>84.0</td><td>1.06 (0.96–1.17)</td></tr></tbody></table>",
      "table_head": "<tr><td>Group</td><td>No. subjects</td><td>PYFU</td><td>Incident HIV infections</td><td>Incidence rate (per 100 PYFU)</td><td>Rate ratio (95% CI)</td></tr><tr><td>TDF/FTC</td><td>2693</td><td>4386</td><td>11</td><td>0.251</td><td>REF</td></tr>",
      "caption": "DISCOVER trial: primary outcome analysis",
      "footnotes": [
        "a Applying counterfactual placebo incidence rate of 2.06 per 100 PYFU (lower 2.5% credibility limit)"
      ],
      "citations": [
        "The trial was expected to generate approximately 72 endpoints per arm, but the observed HIV incidence was much lower, with only 11 and 6 incident HIV infections in the TDF-FTC and TAF-FTC arms, respectively (Table 2)."
      ]
    },
    "PMC9624454_2": {
      "html_table": "<table><thead><tr><th>HIV Exposure</th><th>No.</th><th>CMV Viremia, No. (%), P Value</th><th>CMV Viremia ≤ 1000 IU/mL, No. (%), P Value</th><th>log10 CMV IU/mL in Viremics, Median (IQR), P Value</th></tr></thead><tbody><tr><td>All children</td><td>1024</td><td>314 (30.7)</td><td>59 (5.8)</td><td>2.3 (1.9–2.7)</td></tr><tr><td>HIV unexposed</td><td>872</td><td>253 (29.0)</td><td>45 (5.2)</td><td>2.3 (1.9–2.7)</td></tr><tr><td>HIV exposed<sup>a</sup></td><td>118</td><td>45 (38.1), P = .061<sup>b</sup></td><td>10 (8.5), P = .18<sup>c</sup></td><td>2.4 (2.0–2.9), P = .24<sup>d</sup></td></tr><tr><td>HIV exposed uninfected</td><td>97</td><td>36 (37.1), P = .088<sup>b</sup></td><td>6 (6.2), P = .56<sup>c</sup></td><td>2.4 (1.9–2.7), P = .74<sup>d</sup></td></tr><tr><td>HIV infected</td><td>15</td><td>6 (40.0), P = .39<sup>b</sup></td><td>3 (20.0), P = .015<sup>c</sup></td><td>3.2 (2.6–5.3), P = .012<sup>d</sup></td></tr></tbody></table>",
      "table_head": "<thead><tr><th>HIV Exposure</th><th>No.</th><th>CMV Viremia, No. (%), P Value</th><th>CMV Viremia ≤ 1000 IU/mL, No. (%), P Value</th><th>log10 CMV IU/mL in Viremics, Median (IQR), P Value</th></tr></thead><tbody><tr><td>All children</td><td>1024</td><td>314 (30.7)</td><td>59 (5.8)</td><td>2.3 (1.9–2.7)</td></tr><tr><td>HIV unexposed</td><td>872</td><td>253 (29.0)</td><td>45 (5.2)</td><td>2.3 (1.9–2.7)</td></tr></tbody>",
      "caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection.",
      "footnotes": [
        "a. HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown.",
        "b. Comparison to CMV detection in HIV-unexposed children, χ² test.",
        "c. Comparison to CMV detection ≤ 1000 IU/mL in HIV-unexposed children, χ² test.",
        "d. Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test."
      ],
      "citations": [
        "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels ≤ 1000 IU/mL (Table 2)."
      ]
    },
    "PMC5574138_3": {
      "html_table": "<table frame=\"hsides\" rules=\"groups\"><thead><tr><th>Covariate</th><th>Estimate</th><th>S.E</th><th>95%CI</th></tr></thead><tbody><tr><td>Length of follow-up</td><td>&#x02212;&#x02009;0.0138</td><td>0.0666</td><td>(&#x02212;&#x02009;0.1322&#x02013;0.1046)</td></tr><tr><td>Median CD4 count</td><td>&#x02212;&#x02009;0.0034</td><td>0.0066</td><td>(&#x02212;&#x02009;0.0150&#x02013;0.0079)</td></tr><tr><td>Median age</td><td>0.0415</td><td>0.0503</td><td>(&#x02212;&#x02009;0.1013&#x02013;0.0755)</td></tr><tr><td>Year of publication</td><td>0.0637</td><td>0.0815</td><td>(&#x02212;&#x02009;0.1736&#x02013;0.0980)</td></tr><tr><td>Female proportion</td><td>&#x02212;&#x02009;0.5305</td><td>1.4575</td><td>(&#x02212;&#x02009;3.6792&#x02013;2.6183)</td></tr></tbody></table>",
      "table_head": "<thead><tr><th>Covariate</th><th>Estimate</th><th>S.E</th><th>95%CI</th></tr></thead><tbody><tr><td>Length of follow-up</td><td>&#x02212;&#x02009;0.0138</td><td>0.0666</td><td>(&#x02212;&#x02009;0.1322&#x02013;0.1046)</td></tr><tr><td>Median CD4 count</td><td>&#x02212;&#x02009;0.0034</td><td>0.0066</td><td>(&#x02212;&#x02009;0.0150&#x02013;0.0079)</td></tr></tbody>",
      "caption": "Parameter estimates of meta-regression",
      "footnotes": [],
      "citations": ["Meta regression was performed to determine whether there is a significant association between independent variables in the form of study versus the dependent variable. A regression model is constructed for covariates, length of follow-up, median CD4 cell counts, median age, and year of publication, and proportion of female."]
    },
    "PMC6158807_3": {
      "html_table": "<table><thead><tr><th align=\"left\"></th><th align=\"left\">No. of event</th><th align=\"left\">Person-year of follow-up</th><th align=\"left\">Rate per 100 person-year, 95% CI</th></tr></thead><tbody><tr><td align=\"left\">Composite endpoint (n = 692)</td><td align=\"char\">123</td><td align=\"char\">4071</td><td align=\"char\">3.02 (2.53–3.61)</td></tr><tr><td align=\"left\" colspan=\"4\">Current CD4/CD8 ratio*</td></tr><tr><td align=\"left\">&lt; 0.3</td><td align=\"char\">21</td><td align=\"char\">184</td><td align=\"char\">11.42 (7.45–17.52)</td></tr><tr><td align=\"left\">0.30–0.45</td><td align=\"char\">28</td><td align=\"char\">496</td><td align=\"char\">5.64 (3.90–8.17)</td></tr><tr><td align=\"left\">&gt; 0.45</td><td align=\"char\">72</td><td align=\"char\">3227</td><td align=\"char\">2.23 (1.77–2.81)</td></tr></tbody></table>",
      "table_head": "<thead><tr><th align=\"left\"></th><th align=\"left\">No. of event</th><th align=\"left\">Person-year of follow-up</th><th align=\"left\">Rate per 100 person-year, 95% CI</th></tr></thead><tbody><tr><td align=\"left\">Composite endpoint (n = 692)</td><td align=\"char\">123</td><td align=\"char\">4071</td><td align=\"char\">3.02 (2.53–3.61)</td></tr><tr><td align=\"left\" colspan=\"4\">Current CD4/CD8 ratio*</td></tr></tbody>",
      "caption": "Number of composite endpoint events with CD4/CD8 ratio",
      "footnotes": ["* p < 0.001 for long rank test"],
      "citations": ["The incidence rates of non-AIDS composite events were significantly different between the cutoffs for CD4/CD8 ratio, with 11.42 per 100 PYS (95% CI 7.45–17.52) for current CD4/CD8 ratio < 0.3 and 2.23 per 100 PYS (1.77–2.81) for ratio > 0.45 (Table 3)."]
    },
    "PMC7522205_2": {
    "html_table": "<table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\" rowspan=\"2\">HIV-1 Genotype</th><th align=\"left\" rowspan=\"2\">Patients, no. (%)</th><th align=\"left\" rowspan=\"2\">CD4+ median (IQR)</th><th align=\"left\" colspan=\"3\">Unadjusted</th><th align=\"left\" colspan=\"3\">Adjusted</th></tr><tr><th align=\"left\">Coefficient</th><th align=\"left\">95% CI</th><th align=\"left\"><i>P</i></th><th align=\"left\">Coefficient</th><th align=\"left\">95% CI</th><th align=\"left\"><i>P</i></th></tr></thead><tbody><tr><td align=\"left\">Total</td><td align=\"left\">2845 (100.0)</td><td align=\"char\">160 (49–310)</td><td align=\"left\"></td><td align=\"char\"></td><td align=\"char\"></td><td align=\"left\"></td><td align=\"char\"></td><td align=\"char\"></td></tr><tr><td align=\"left\">CRF01_AE</td><td align=\"left\">1687 (59.3)</td><td align=\"char\">111 (31–279)</td><td align=\"left\">0</td><td align=\"char\"></td><td align=\"char\"></td><td align=\"left\">0</td><td align=\"char\"></td><td align=\"char\"></td></tr><tr><td align=\"left\">CRF07_BC</td><td align=\"left\">254 (8.9)</td><td align=\"char\">250 (156–377)</td><td align=\"left\">139</td><td align=\"char\">(117–161)</td><td align=\"char\">&lt;0.001</td><td align=\"left\">113</td><td align=\"char\">(86–140)</td><td align=\"char\">&lt;0.001</td></tr><tr><td align=\"left\">CRF08_BC</td><td align=\"left\">728 (25.6)</td><td align=\"char\">205 (108–327)</td><td align=\"left\">94</td><td align=\"char\">(73–115)</td><td align=\"char\">&lt;0.001</td><td align=\"left\">80</td><td align=\"char\">(65–95)</td><td align=\"char\">&lt;0.001</td></tr><tr><td align=\"left\">Others</td><td align=\"left\">176 (6.2)</td><td align=\"char\">198 (89–355)</td><td align=\"left\">87</td><td align=\"char\">(46–128)</td><td align=\"char\">&lt;0.001</td><td align=\"left\">72</td><td align=\"char\">(37–107)</td><td align=\"char\">&lt;0.001</td></tr></tbody></table>",
    "table_head": "<thead><tr><th>HIV-1 Genotype</th><th>Patients, no. (%)</th><th>CD4+ median (IQR)</th><th colspan=\"3\">Unadjusted</th><th colspan=\"3\">Adjusted</th></tr><tr><th></th><th></th><th></th><th>Coefficient</th><th>95% CI</th><th><i>P</i></th><th>Coefficient</th><th>95% CI</th><th><i>P</i></th></tr></thead><tbody><tr><td>Total</td><td>2845 (100.0)</td><td>160 (49–310)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CRF01_AE</td><td>1687 (59.3)</td><td>111 (31–279)</td><td>0</td><td></td><td></td><td>0</td><td></td><td></td></tr>",
    "caption": "Effects of HIV-1 genotype on baseline CD4+ cell counts (cells/μl) among newly diagnosed HIV patients.",
    "footnotes": [
      "Adjusted for age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis."
    ],
    "citations": [
      "Table 2 presents the unadjusted and adjusted effects of HIV-1 genotype on baseline CD4+ cell counts in newly diagnosed HIV patients. Among 2845 patients, the median (IQR) baseline CD4+ cell count was 111 cells/μl (31–279), 250 cells/μl (156–377), 205 cells/μl (108–327), and 198 cells/μl (89–355) for CRF01_AE, CRF07_BC, CRF08_BC, and other genotypes, respectively."
    ]
  },
  "PMC9008168_2": {
    "html_table": "<table frame=\"hsides\" rules=\"groups\"><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><col align=\"left\" span=\"1\"/><thead><tr><th></th><th>Unadjusted incidence rate (cases/1000 PY)</th><th>95% CI</th><th>HR</th><th>95% CI</th></tr></thead><tbody><tr><td>Participants without HIV</td><td>69.8</td><td>54.7–89.0</td><td>1.00</td><td>Reference</td></tr><tr><td>PLWH on non-TLD ART</td><td>77.1</td><td>69.8–85.2</td><td>1.13</td><td>0.79–1.63</td></tr><tr><td>PLWH on TLD</td><td>73.3</td><td>54.0–99.6</td><td>1.77</td><td>1.22–2.55</td></tr><tr><td>PLWH, ART naïve</td><td>37.7</td><td>24.1–59.1</td><td>0.43</td><td>0.27–0.70</td></tr></tbody></table>",
    "table_head": "<thead><tr><th></th><th>Unadjusted incidence rate (cases/1000 PY)</th><th>95% CI</th><th>HR</th><th>95% CI</th></tr></thead><tbody><tr><td>Participants without HIV</td><td>69.8</td><td>54.7–89.0</td><td>1.00</td><td>Reference</td></tr><tr><td>PLWH on non-TLD ART</td><td>77.1</td><td>69.8–85.2</td><td>1.13</td><td>0.79–1.63</td></tr>",
    "caption": "Unadjusted incidence rates and hazard ratios (HR) of BMI ≥25 kg/m² by HIV and ART status",
    "footnotes": [
      "Abbreviations: PLWH, people living with HIV; TLD, tenofovir/lamivudine/dolutegravir; PY, person-years."
    ],
    "citations": [
      "Of the 2144 participants at risk, 516 participants developed a BMI ≥25 kg/m² (Table 2). Unadjusted incidence rates of developing a high BMI were similar among participants without HIV and those on ART with the highest incidence among participants on non-TLD ART."
    ]
  }
}